Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6152W HIGH $33.60
Volume
95.31 K
Value Traded
275.43 K
Short % Float
3.99%
-16.46%Week
-44.07%1 Month
-86.47%3 Month
-93.29%6 Month
-99.83%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.40 M
EPS (TTM)
-17.49
P/E Ratio
-
Ent. Value
-3.67 M
Total Shares
2.09 M
Float Shares
1.73 M
Insiders
17.07%
Institutions
32.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CRIS Catalyst Timeline
Dated clinical, regulatory and corporate events for Curis, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Curis, Inc.
530Total events
5Upcoming
98Tier-1 (high impact)
2004 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedEmavusertibTrial
First five patients dosed in TakeAim CLL study
Chronic Lymphocytic Leukemia (CLL)source ↗
◆Oral PresentationEmavusertibPresentation
Webcast to discuss positive updated clinical data in PCNSL and provide guidance on year-end CLL data
PCNSL, CLLsource ↗
▲Enrollment UpdateEmavusertibTrial
Number of patients consented increased to 10 in TakeAim CLL study
CLLsource ↗
▲Full ResultsEmavusertibClinical Data
Updated PCNSL data as of July 1, 2026: 100% ORR in BTKi-naïve evaluable patients (5/5), 33% ORR in BTKi-experienced evaluable patients (10/30)
PCNSLsource ↗
▲Enrollment MilestoneEmavusertibTrial
First six patients consented in TakeAim CLL study
chronic lymphocytic leukemia (CLL)source ↗
▲First Patient DosedEmavusertibTrial
First five patients expected to be dosed by end of July 2026
CLLsource ↗
▲Enrollment MilestoneEmavusertibTrial
Eleven clinical sites opened for enrollment in TakeAim CLL study
CLLsource ↗
◆AbstractEmavusertibPresentation
Abstract available online for phase I trial of emavusertib in combination with gemcitabine and nab-paclitaxel in PDAC
pancreatic ductal adenocarcinoma (PDAC)source ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial and Operating Results Report and Conference Call
◆First Patient DosedEmavusertibTrial
Dosing of initial 5 patients in TakeAim CLL combination study with zanubrutinib expected by mid-2026
Chronic Lymphocytic Leukemia (CLL)source ↗
◆Quarterly UpdateCorporate
Fourth Quarter 2025 Financial and Operating Results and Conference Call
▼Equity OfferingCorporate
Closing of January 2026 PIPE Financing with gross proceeds of up to $80.8 million
◆Poster PresentationEmavusertibPresentation
Poster presentation of initial clinical data in gastric and esophageal cancer at ASCO GI Cancers Symposium
gastric and esophageal cancersource ↗
◆Poster PresentationEmavusertibPresentation
Poster presentation of initial clinical data in frontline AML at ASH 2025
Acute Myeloid Leukemiasource ↗
◆Poster PresentationEmavusertibPresentation
Poster presentation of initial clinical data in SCNSL at SNO 2025
Secondary CNS Lymphomasource ↗
▲Trial InitiationEmavusertibTrial
Initiation of Phase 2 study of emavusertib in combination with zanubrutinib in CLL
Chronic Lymphocytic Leukemiasource ↗
▲FDA Feedback ReceivedEmavusertibFDA Meeting
FDA meeting completed in 2025; guidance that ongoing study could support accelerated approval application
PCNSLsource ↗
▲EU MAA SubmissionEmavusertibEx-US Regulatory
EMA CHMP meeting completed in 2025; guidance that ongoing study could support conditional marketing authorization
PCNSLsource ↗
◆Topline ReadoutEmavusertibClinical Data
Preliminary clinical data update from TakeAim Lymphoma study expected in 2023
lymphomasource ↗
▲Clinical Hold LiftedEmavusertibIND
FDA lifts partial clinical hold on monotherapy dose escalation phase (Phase 1a) of TakeAim Leukemia study
relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS)source ↗
▲Clinical Hold LiftedEmavusertibIND
FDA lifts partial clinical hold on TakeAim Lymphoma study of emavusertib
lymphomasource ↗
◆Enrollment UpdateEmavusertibTrial
Resumption of enrollment in TakeAim Lymphoma study expected in Q3 2022
lymphomasource ↗
◆Poster PresentationEmavusertibPresentation
Poster discussion of CA-4948 for melanoma brain metastasis at ASCO 2022
melanoma brain metastasissource ↗
◆Oral PresentationEmavusertibPresentation
Poster discussion of CA-4948 monotherapy or combination at ASCO 2022
relapsed/refractory acute myeloid leukemia or myelodysplastic syndromesource ↗
◆Poster PresentationEmavusertibPresentation
Poster presentation of CA-4948 in combination with FOLFOX/PD-1 inhibitor at ASCO 2022
untreated unresectable gastric and esophageal cancersource ↗
▲Oral PresentationEmavusertibPresentation
Clinical data for emavusertib plus ibrutinib presented at ASCO 2022
B cell malignanciessource ↗
▼Partial Clinical HoldEmavusertibIND
FDA partial clinical hold on TakeAim Lymphoma study
B-cell malignanciessource ↗
▼Partial Clinical HoldEmavusertibIND
FDA partial clinical hold on TakeAim Leukemia study
relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromesource ↗
▼Enrollment PausedEmavusertibTrial
Pause enrollment in TakeAim Lymphoma study pending resolution of partial clinical hold
B-cell malignanciessource ↗
▼Partial Clinical HoldEmavusertibIND
FDA placed partial clinical hold on TakeAim Leukemia and TakeAim Lymphoma studies
relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, hematologic malignanciessource ↗
●Preclinical PoCEmavusertibPreclinical
Publication from Washington University suggests potential of emavusertib in pancreatic cancer
pancreatic cancersource ↗
▲Oral PresentationEmavusertibPresentation
Presented positive updated data for CA-4948 monotherapy in R/R AML/MDS
Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromessource ↗
▲Oral PresentationCI-8993Presentation
Presented initial clinical data from Phase 1 study of CI-8993
Relapsed or Refractory Solid Tumorssource ↗
◆Topline ReadoutEmavusertibClinical Data
Updated data for emavusertib in AML/MDS monotherapy
Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromessource ↗
◆Timing GuidanceEmavusertibPresentation
Clinical data update in January 2022 on CA-4948 monotherapy study
Acute Myeloid Leukemia or Myelodysplastic Syndromes with spliceosome mutationsource ↗
◆Timing GuidanceCI-8993Presentation
Initial safety data from CI-8993 Phase 1 study expected in January 2022
Relapsed/Refractory solid tumorssource ↗
▲Topline ReadoutEmavusertibClinical Data
Safety and efficacy data update for CA-4948 in AML/MDS with data extraction date Dec 16, 2021
Relapsed/Refractory AML and high-risk MDSsource ↗
Past FDA Catalysts and PDUFA Decisions
How CRIS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-21 | emavusertib (CA-4948) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$2M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.0x
rNPV / MCap
Top 80%
Micro Cap(rank 527 of 658)
Percentile Rank
Curis, Inc. faces pipeline headwinds (26/100), with $502M risk-adjusted pipeline value, led by Emavusertib in Chronic Lymphocytic Leukemia (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emavusertib Small moleculeNCT07271667 | Chronic Lymphocytic Leukemia | Phase 2 | RECRUITING | 108 | Nov 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRIS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| emavusertib Orphan | Primary CNS Lymphoma (PCNSL) and Chronic Lymphocytic Leukemia (CLL) | Phase 2 | 2026-07-22 | PCNSL: BTKi naïve ORR 100%, patients 5, BTKi experienced ORR 33%, patients 30Read More | Curis Announces Positive Emavusertib UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rubin MarcDirector | Grant/Award | 6,800 6,800 held | $5.29 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRIS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 0.1 % | 390.00 K | 185.94 K | -6.19% ( -12.27 K) |
CRIS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRIS ranks across every disease it competes in
Competitive Position is a premium feature
See how CRIS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRIS News
CRIS▲ +12%on this news
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
Curis, Inc. has announced the pricing of a public offering aimed at raising approximately $5.6 million. The offering involves the sale of 3,733,334 shares of common stock and warrants, with proceeds intended for research and development activities. The offering is set to close on or about August 14, 2026, subject to market conditions.
Read more →CRISCuris Doses First Five Patients in TakeAim CLL Study
Curis, Inc. has announced a significant milestone in its TakeAim CLL study by dosing the first five patients with Chronic Lymphocytic Leukemia. The company expects to report initial data from the study by December 2026. The combination of emavusertib and BTK inhibitors may enhance treatment outcomes, addressing the unmet needs in CLL management.
Read more →CRISAssureCare® and CURIS Partner to Ensure RHT Funding Builds Infrastructure That Outlasts the Program
AssureCare and CURIS have partnered to help Federally Qualified Health Centers (FQHCs) effectively utilize funding from the CMS Rural Health Transformation (RHT) program. This partnership aims to create sustainable healthcare infrastructure by integrating care management and technology. They will discuss their approach in a live webinar on July 28, 2026, emphasizing the importance of connected systems in improving patient outcomes.
Read more →CRISCuris Announces Positive Emavusertib Update
Curis, Inc. announced positive updates on its emavusertib clinical trials, particularly in the TakeAim Lymphoma study for Primary CNS Lymphoma (PCNSL) and the TakeAim CLL study for Chronic Lymphocytic Leukemia (CLL). The company reported strong response rates in BTK-naïve and BTK inhibitor-experienced patients. Additionally, Curis is increasing its guidance for year-end data in the CLL study, reflecting strong enrollment interest.
Read more →CRIS▼ -8.3%on this news· ran to -23% by day 3
Curis Consents First Six Patients in TakeAim CLL Study
Curis, Inc. has reached a significant milestone by consenting the first six patients in its TakeAim CLL study, which aims to evaluate emavusertib in combination with zanubrutinib for chronic lymphocytic leukemia. The company expects to dose five patients by the end of July 2026, with initial data anticipated in December 2026. The study reflects strong interest from clinical sites and highlights the unmet need in CLL treatment.
Read more →CRIS▲ +43.6%on this news· ran to +98% by day 1
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis, Inc. has opened eleven clinical sites for patient enrollment in its Phase 2 TakeAim CLL study, which evaluates emavusertib in combination with zanubrutinib for Chronic Lymphocytic Leukemia. The company reaffirmed its dosing guidance for the initial five patients by July 2026, with data expected by December 2026. Additionally, stockholders approved a reverse stock split to comply with NASDAQ requirements.
Read more →CRISCuris Provides First Quarter 2026 Business Update
Curis, Inc. provided a business update for Q1 2026, highlighting the ongoing clinical trials of emavusertib, an IRAK4 and FLT3 inhibitor. The drug is being tested in combination with other therapies for conditions like relapsed or refractory primary CNS lymphoma and chronic lymphocytic leukemia. Despite promising developments, the company reported a net loss of $24.2 million and no revenues for the quarter.
Read more →CRISCuris to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
Curis, Inc. will report its first quarter 2026 financial and operational results on May 12, 2026. The company will also host a conference call and webcast for investors. Curis is focused on developing emavusertib, an IRAK4 and FLT3 inhibitor, currently in various clinical trials for lymphoma and leukemia. The company has received Orphan Drug Designation for several indications.
Read more →CRISCuris Provides Fourth Quarter 2025 Business Update
Curis, Inc. provided a business update for Q4 2025, reporting a net income of $19.4 million, a significant improvement from a loss in the same quarter of 2024. The company raised up to $80.8 million through a private placement and reported decreased research and development expenses. However, Curis also noted a net loss for the year and a decline in royalty revenues.
Read more →CRIS▼ -5.9%on this news· ran to -19% by day 3
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
Curis, Inc. will report its fourth quarter 2025 financial and operating results on March 19, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Curis is focused on the development of emavusertib, which is being evaluated in various clinical studies for different cancers.
Read more →CRISCuris Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Curis, Inc. has successfully closed a private placement, securing gross proceeds of up to $80.8 million. The financing was led by notable institutional investors and included participation from the company's management team. The funds will support the development of emavusertib, a small molecule IRAK4 and FLT3 inhibitor, currently in clinical trials for various cancers.
Read more →CRIS▼ -16%on this newsshared move
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Curis, Inc. has announced a private placement financing agreement expected to yield up to $80.8 million in gross proceeds. The financing will support the development of emavusertib, a small molecule IRAK4 and FLT3 inhibitor. The deal includes the sale of preferred stock and warrants, with an initial close anticipated shortly. However, the securities are not registered under the Securities Act, and stockholder approval is required for some aspects of the deal.
Read more →CRISCuris Provides Updated Data from its Frontline AML Triplet Study
Curis, Inc. presented updated data from its frontline AML triplet study at the 67th ASH Annual Meeting, showing that 62.5% of patients achieved undetectable MRD after treatment with emavusertib combined with venetoclax and azacitidine. The study aims to improve outcomes for AML patients who remain MRD-positive after achieving complete remission. The data indicates promising efficacy without changes to the safety profile.
Read more →CRIS▲ +17.7%on this news
Curis to Present at Upcoming 30th Annual SNO Meeting
Curis, Inc. will present clinical and preclinical data on emavusertib at the 30th Annual SNO Meeting. The presentations will focus on its efficacy in treating Primary and Secondary CNS Lymphoma. Notable speakers include Dr. Christian Grommes and Dr. Lakshmi Nayak, highlighting the drug's potential in combination therapies. Emavusertib has received Orphan Drug Designation for multiple indications.
Read more →CRISCuris Provides Third Quarter 2025 Business Update
Curis, Inc. reported its Q3 2025 financial results, highlighting advancements in clinical studies for emavusertib in treating PCNSL, CLL, and AML. The company is preparing for presentations at the SNO and ASH annual meetings and aims for accelerated approval in PCNSL. Despite progress, Curis faces financial challenges with a reported net loss and limited cash reserves.
Read more →CRISCuris to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
Curis, Inc. will announce its third quarter 2025 financial and operational results on November 6, 2025. A conference call and webcast will follow the announcement, allowing participants to engage directly with management. The company continues to develop emavusertib, an IRAK4 inhibitor, in various clinical studies for serious hematological conditions.
Read more →CRISCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. announced the approval of inducement stock options for two new employees, totaling 84,750 shares. The options have a grant date of October 1, 2025, and are part of the company's strategy to attract talent. Additionally, Curis is advancing its IRAK4 inhibitor, emavusertib, in several clinical studies.
Read more →CRISCuris to Present at Upcoming Healthcare Conferences in September
Curis, Inc. will present at two upcoming healthcare conferences in September 2025. CEO James Dentzer will participate in a fireside chat at the Cantor Global Healthcare Conference and a company presentation at the H.C. Wainwright Global Investment Conference. The presentations will highlight Curis's development of emavusertib, an IRAK4 inhibitor.
Read more →CRISCuris Provides Second Quarter 2025 Business Update
Curis, Inc. reported its Q2 2025 financial results, highlighting progress in its clinical studies for emavusertib, particularly in lymphoma and leukemia. The company is expanding its studies to include combinations with BTK inhibitors, which could significantly impact treatment paradigms. Despite a net loss of $8.6 million, Curis is optimistic about upcoming data and continued patient enrollment.
Read more →About Curis, Inc.
Headquarters128 SPRING STREET, LEXINGTON, MA, 02421
BIOPHARMAWATCH ELITE PLUS
Trade the next CRIS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime